With over 98% accuracy, our MCED test is capable of detecting metabolic changes in cancer cells, which makes it an ideal option for early-stage screening including Stage 1 and 2. Its non-invasive nature and quick turnaround time make it convenient for patients. This blood-based screening test has the potential to transform cancer detection and enhance patient outcomes by detecting the disease when it is most treatable.
OncoVeryx-F is the most accurate early-stage multi cancer detection test to screen for cancers in high-risk and asymptomatic women.
OncoVeryx-F is a proprietary technology, developed by PredOmix, that integrates metabolomics with deep learning to drive early cancer detection in a single non-invasive test.
OncoVeryx-F detects the presence or absence of cancer and identifies the Tissue Of Origin (TOO) in a single test.
OncoVeryx-F has the capability to identify cancer in its early stages, including Stage 1 and 2, leading to a higher likelihood of successful treatment and ultimately saving lives.
download our brochure
Regular screening tests facilitate early detection of breast cancer, but asymptomatic early stages can be challenging. Factors like age, breast density, family history, and hormones influence detection, and understanding these factors is crucial in devising screening strategies.
Traditional breast cancer screening methods, such as mammography and clinical breast exams, have some weaknesses, including false negatives, false positives, limited detection, radiation exposure, and inconvenience.While they have been successful in detecting breast cancer in many women, there is ongoing research into new and improved screening methods that can detect breast cancer at an early stage, making a significant difference in patient outcomes. Early detection of breast cancer is crucial, as the survival rate is high when breast cancer is detected early.
OncoVeryx-F is well-suited for early-stage screening to accurately detect breast cancer.
download our brochure
Endometrial cancer is a common gynecologic cancer that may not have noticeable symptoms in its early stages, making it difficult to detect without screening.
Currently available screening methods for endometrial cancer, such as transvaginal ultrasound and endometrial biopsy, may have limitations in detecting early-stage disease and may be uncomfortable or invasive. Other factors such as age, menopausal status, obesity,hormonal factors, and family history can also affect detection.
OncoVeryx-F offers a revolutionary approach to detect endometrial cancer, making it a value tool for improving patient outcomes.
download our brochure
Cervical cancer is a serious and potentially life-threatening disease that can be treated more effectively when detected in its early stages. Early detection can be achieved through regular screening tests, but certain factors like HPV infection and lack of access to healthcare can make it challenging. Women should be aware of the risk factors for cervical cancer and take appropriate measures to reduce their risk, such as getting vaccinated against HPV. It is crucial for women to understand the importance of regular cervical cancer screening to increase the likelihood of successful treatment and improve patient outcomes.
OncoVeryx-F can help address the challenges in early detection of cervical cancer. Our test allows for the accurate detection of cervical cancer at an early stage, which is critical for improved patient outcomes.
download our brochure
Ovarian cancer is often called the silent killer because it can grow and spread without causing noticeable symptoms until it reaches an advanced stage. However, if detected early, the survival rate is high. Furthermore, the disease can become resistant to treatment, so early detection and treatment are critical.
OncoVeryx-F can assist in overcoming the difficulties in detecting ovarian cancer in its early stages. Our screening test can precisely identify ovarian cancer at an early stage and provide valuable insights to aid in making informed decisions regarding diagnosis and early intervention.
download our brochure
OncoVeryx-F is a non-invasive blood-based screening method for early detection of four specific cancers in women.
OncoVeryx-F is a non-invasive blood-based screening method for early detection of four specific cancers in women. The test requires only 0.1 mL of serum sample.
OncoVeryx-F offers numerous benefits including:
No need for invasive procedures:
The test involves a simple blood draw, which is less invasive than traditional cancer screening methods like mammographies.
Early detection:
OncoVeryx-F can detect cancer at an early stage, providing the best chance for successful treatment.
Increased convenience:
As a non-invasive test, OncoVeryx-F provides increased convenience for women who may otherwise avoid cancer screening due to discomfort or inconvenience.
OncoVeryx-F utilizes metabolomics integrated with a proprietary deep learning algorithm for highly accurate cancer screening.
OncoVeryx-F utilizes metabolomics integrated with a proprietary deep learning algorithm for highly accurate cancer screening.
Metabolomics, a rapidly evolving field, characterizes the unique metabolic signature of cellular processes. Through a
combination of advanced LC-MS/MS techniques and cutting-edge
computational methods, our proprietary deep learning algorithm analyzes
the complex metabolic profiles of individuals and identifies
characteristic patterns that are indicative of cancer. This technology
enables the detection of early-stage cancer with high accuracy and
specificity, providing a significant advancement in cancer screening.
Our algorithm also allows for the simultaneous detection of multiple
cancer types, enhancing the efficiency and
effectiveness of screening. Our approach has the potential to
revolutionize cancer diagnosis and treatment by facilitating early
detection and improving patient outcomes.
OncoVeryx-F simultaneously detects the four most prominent women-specific cancers including breast, endometrial, cervical and ovarian cancers with the highest accuracy.
OncoVeryx-F simultaneously detects the four most prominent women-specific cancers including breast, endometrial, cervical and ovarian cancers with the highest accuracy.
OncoVeryx-F can save millions of lives by detecting
cancer at an early stage when it is most treatable. The
non-invasive nature of the test allows for early detection
without the need for invasive procedures, reducing patient
discomfort and healthcare costs. Additionally, the high
accuracy of the test with over 98% specificity and
sensitivity allows for reliable identification of cancer,
reducing the risk of false negatives and missed diagnoses.
Early detection of cancer can lead to more effective
treatment options, including less aggressive therapies,
resulting in improved patient outcomes and quality of life.
By revolutionizing cancer screening with its innovative
technology and cutting-edge methodology, OncoVeryx-F
has the potential to significantly reduce cancer-related
mortality rates worldwide.
Regular cancer screening is vital for everyone, including asymptomatic individuals. Together, let's prioritize preventive care and empower you to make informed decisions for a healthier future.
Over 98% accuracy
Counselling and consulting support
Home collection available
Safe and affordable
Our test has the potential to detect cancer at an early stage, when it is more treatable. This could lead to improved outcomes and reduced mortality rates.
Our proprietary technology combines metabolomics and deep learning, allowing us to analyze an individual’s metabolites to identify potential cancer signatures and use sophisticated machine-learning algorithms to enhance diagnostic accuracy.
Our non-invasive blood test offers a painless and safe option for individuals that reduces the risk of complications and enables more frequent monitoring for at-risk individuals, prioritizing patient comfort.
Our non-invasive blood test for early cancer detection is so convenient that samples can be easily collected from the comfort of a patient's home, making the screening process even more accessible and patient-friendly.
Our 7 day turnaround time (TAT) for test results ensures that patients receive timely and accurate information, allowing for prompt follow-up care and peace of mind.
We are committed to providing affordable pricing for our early cancer detection test, ensuring that patients have better access to this critical screening option.
The OncoVeryx-F test is a non-invasive blood test that can detect the presence or absence of cancer by analysing the metabolic signatures or patterns in the bloodstream. The OncoVeryx-F test can be used as a tool for cancer screening, particularly for patients at higher risk for developing cancer.
The OncoVeryx-F test is recommended for,
• Individuals above 45 years of age or older at elevated risk of cancer
• Asymptomatic individuals opting for general cancer screening
• Individuals with genetic vulnerabilities and family history of cancers
• Women with suspicious mammography, PAP, and/or HPV results
• Individuals who cannot undergo invasive screening tests like colonoscopy and endoscopy
• Men opting for PSA tests The test should be used in addition to other recommended cancer screening methods.
The OncoVeryx-F test has a high level of accuracy, with a sensitivity of up to 98% and a specificity of over 98%. However, like all medical tests, it is not 100% accurate.
The OncoVeryx-F test can detect four women specific cancers along with the Tissue Of Origin (TOO).
The test is not advisable for individuals who have autoimmune disease, high-grade dysplasia, chronic kidney disease, or a history of cancer. The test is not recommended for pregnant women.
A simple blood draw of 1ml is all that is needed for the test.
Once the sample reach our lab, results from the OncoVeryx-F test typically take 7-10 business days to be processed and returned to the ordering physician.
If you receive a positive result from the OncoVeryx-F test, you should discuss the results with your doctor to determine next steps for further testing and treatment.
The OncoVeryx-F test is a non-invasive blood test and does not pose any significant risks or side effects.
The OncoVeryx-F test is available through healthcare providers and can be ordered by a physician. The test can also be ordered online through our website by scanning the QR code. Patients should discuss their interest in the test with their healthcare provider to determine if it is right for them.
Our representatives can help with sample collection at the hospital site or our lab premises in Gurgaon, India. We also offer home collection services in select locations.
The test is performed at the PredOmix R&D and testing facility in Gurugram, India.
OncoVeryx-F test is unique in its ability to detect cancer at earlier stages, including Stage 1 cancer, with higher accuracy than traditional screening tests. It can also detect a wider range of cancer types, even before the cancer can be detected by current diagnostic methods.
The OncoVeryx-F is not a DNA, genetic or CT-DNA test. DNA based tests are types of genetic testing that analyze DNA mutations and gene variations that may be associated with cancer and help in identifying the risk of developing certain types of cancer. OncoVeryx-F is a metabolite-based test which analyses the real time metabolic signatures of cancer cells in the blood stream from very early stages, with higher specificity and sensitivity than DNA tests.
Since this is a screening test, it is recommended to take the test on a yearly basis or as advised by the healthcare practitioner.
Fasting is not required for the test and the sample can be drawn at any time during the day. Our team of medical professionals is available to assist you throughout the entire testing process. If you have any questions or concerns regarding the test, please don't hesitate to contact us for guidance and support.
A member of our team will contact you shortly.
